OVA Peptide(257-264) acetate salt
Based on 25 publication(s) in Google Scholar
OVA Peptide(257-264) acetate salt is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
For research use only. We do not sell to patients.
- Formula: C47H78N10O15
- Molecular Weight:1023.18
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) OVA Peptide(257-264) acetate salt
More- Signal Transduct Target Ther. 2026 Jul 24;11(1):290.
- Signal Transduct Target Ther. 2026 Apr 28;11(1):156. [Abstract]
- Cancer Cell. 2026 Jun 11:S1535-6108(26)00257-6. [Abstract]
- Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
- Cancer Cell. 2025 Sep 8;43(9):1758-1775.e8. [Abstract]
- Cell. 2026 Jun 25;189(13):3922-3939.e20. [Abstract]
- Immunity. 2026 Jul 3:S1074-7613(26)00253-0.
- Nat Commun. 2025 Sep 2;16(1):8181. [Abstract]
- Mol Cell. 2024 Mar 21;84(6):1120-1138.e8. [Abstract]
- Adv Sci (Weinh). 2026 Mar 13:e18525. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(45):e2404756. [Abstract]
- Biomaterials. 2026 Jun:329:123925. [Abstract]
- J Control Release. 2026 Jul 10:395:115032. [Abstract]
- J Control Release. 2026 Jul 18:398:115176.
- Cell Death Dis. 2025 Jun 20;16(1):462. [Abstract]
- Cell Commun Signal. 2024 Aug 27;22(1):413. [Abstract]
- Mol Ther. 2026 Jun 2:S1525-0016(26)00470-3. [Abstract]
- J Med Chem. 2026 Apr 23;69(8):9603-9614. [Abstract]
- J Med Chem. 2026 Feb 26;69(4):4900-4912. [Abstract]
- OncoImmunology. 2022 Feb 9;11(1):2034257. [Abstract]
- Nutrients. 2024 Oct 22;16(21):3577. [Abstract]
- Pathol Res Pract. 2025 Jun:270:155975. [Abstract]
- bioRxiv. 2026 Apr 28.
- BIO Web of Conferences. 2025 Jul 2.
- bioRxiv. 2023 Jan 31.
Customer Validation & Images
-
Flow Cytometry
-
Cell Imaging/Staining
Biological Activity
Description
In Vitro
TAP1-I- and C57BL/6 macrophages may process Crl-OVA and full-length OVA in different cellular compartments and that the protein context of the OVA Peptide(257-264) epitope influences the extent of TAP-independent processing for MHC class I presentation. OVA Peptide(257-264) epitope is presented with a differential dependence on the TAP transporter depending on the protein context of the OVA epitope: OVA Peptide(257-264) contained within the MBPCrl-OVA or Crl-OVA bacterial fusion proteins is presented with little dependence on the TAP transporter, while OVA Peptide(257-264) contained within full-length ovalbumin is largely dependent on the TAP transporter, regardless of whether recombinant OVA is expressed in bacteria or the native protein is coupled to polystyrene beads[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Chemical Information
-
Molecular Weight 1023.18
-
Formula C47H78N10O15
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (25)
-
Journal Impact Factor
-
Most Recent
-
-
Signal Transduct Target Ther
Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. [Abstract]2026 Apr 28;11(1):156. PMID: 42045172 -
Cancer Cell
Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer. [Abstract]2026 Jun 11:S1535-6108(26)00257-6. PMID: 42276047 -
Cancer Cell
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]2026 Mar 9;44(3):658-675.e12. PMID: 41687606 -
Cancer Cell
DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. [Abstract]2025 Sep 8;43(9):1758-1775.e8. PMID: 40816293 -
Cell
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers. [Abstract]2026 Jun 25;189(13):3922-3939.e20. PMID: 42102817 -
-
Nat Commun
Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC. [Abstract]2025 Sep 2;16(1):8181. PMID: 40897711 -
Mol Cell
2024 Mar 21;84(6):1120-1138.e8. PMID: 38377992 -
Adv Sci (Weinh)
Context-Dependent Role of GDF15: GDF15+ Tumor-Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis. [Abstract]2026 Mar 13:e18525. PMID: 41824793 -
Adv Sci (Weinh)
ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis-Associated Hepatocellular Carcinoma by Modulating Tumor-Associated Macrophages. [Abstract]2024 Dec;11(45):e2404756. PMID: 39377228 -
Biomaterials
2026 Jun:329:123925. PMID: 41453350 -
J Control Release
STING agonist-primed supramolecular oncolytic hydrogel vaccine for tuning tumors against themselves. [Abstract]2026 Jul 10:395:115032. PMID: 42155600 -
-
Cell Death Dis
ISCU-p53 axis orchestrates macrophage polarization to dictate immunotherapy response in esophageal squamous cell carcinoma. [Abstract]2025 Jun 20;16(1):462. PMID: 40541964 -
Cell Commun Signal
Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2. [Abstract]2024 Aug 27;22(1):413. PMID: 39192276 -
Mol Ther
Nicotinamide riboside enhances adoptive T cell therapy by promoting memory differentiation and metabolic fitness. [Abstract]2026 Jun 2:S1525-0016(26)00470-3. PMID: 42231576 -
J Med Chem
Dual-Functional Anti-SIRPα-cGAMP Conjugate Reprograms the Tumor Immune Microenvironment and Enhances Antitumor Immunity. [Abstract]2026 Apr 23;69(8):9603-9614. PMID: 41918375 -
J Med Chem
Modulation of Tumor Microenvironment via Antibody Mediated Precision Delivery of CpG to Myeloid Cell. [Abstract]2026 Feb 26;69(4):4900-4912. PMID: 41649040 -
OncoImmunology
Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer. [Abstract]2022 Feb 9;11(1):2034257. PMID: 35154907 -
Nutrients
Effect of Nicotinamide Riboside Against the Exhaustion of CD8+ T Cells via Alleviating Mitochondrial Dysfunction. [Abstract]2024 Oct 22;16(21):3577. PMID: 39519411 -
Pathol Res Pract
SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion. [Abstract]2025 Jun:270:155975. PMID: 40228401 -
-
OVA Peptide(257-264) acetate salt purchased from MedChemExpress. Usage Cited in: BIO Web of Conferences. 2025 Jul 2.
OT-1 CD8+ T cells were stimulated with OVA Peptide(257-264) TFA (SIINFEKL peptide) (1 ug/mL; 24-48 h) and sampled for CFSE detection via flow cytometry.
OVA Peptide(257-264) acetate salt purchased from MedChemExpress. Usage Cited in: BIO Web of Conferences. 2025 Jul 2.
B16F10-FLuc cells were pre-treated with/without OVA Peptide(257-264) TFA (SIINFEKL peptide) (25 nM; 2 h) and then co-cultured with OT-1 CD8+ T cells for 4 h. Luminescence was measured by mixing 50 μL of supernatant with 100 μL of luciferase substrate.
-
Solvent & Solubility
In Vitro
H2O
Peptide Solubility and Storage Guidelines:
1. Calculate the length of the peptide.
2. Calculate the overall charge of the entire peptide according to the following table:
| Contents | Assign value | |
|---|---|---|
| Acidic amino acid | Asp (D), Glu (E), and the C-terminal -COOH. | -1 |
| Basic amino acid | Arg (R), Lys (K), His (H), and the N-terminal -NH2 | +1 |
| Neutral amino acid | Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) | 0 |
3. Recommended solution:
| Overall charge of peptide | Details |
|---|---|
| Negative (<0) |
1. Try to dissolve the peptide in water first. 2. If water fails, add NH4OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
| Positive (>0) |
1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
| Zero (=0) |
1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
OVA Peptide(257-264) acetate salt Related Classifications
HY-P1489B Related Classifications
Powered by Bioz